Provide calibration and repair services for laboratory instruments. Offer proprietary software solutions for asset management and workflow integration. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
The gap is $123.9M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 146.8× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 37% of them.
Analysts' average target sits 47% above today's price.
The stock trades 41% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 13% a year on average.
Over the last 12 months, company executives reported 60 buys and 40 sells. Management buying with its own money is usually read as a good sign.
The company’s market value is 147 times its annual profit. Even a small disappointment could hit the price hard.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 37/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, TRNS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TRNS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Analysts’ average target sits above today’s price, yet the valuation grade (37/100) says the stock isn’t cheap.